EGFR and lung cancer: A study with Vandetanib reported that when radiation therapy is combined concomitantly with VEGFR2 and EGFR blockade, a significant enhancement of anti-angiogenic, anti-vascular, and anti-tumour effects is seen in an orthotopic model of lung cancer (Kerbel, 2008).